Skip to content

AHA/ACC/HFSA 2022: heart failure

International AHA/ACC/HFSA Current

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

Heidenreich PA, et al. Circulation. 2022;145:e895–e1032
DOI 10.1161/CIR.0000000000001063 · Summary checked against the source: 2026-11

Read or download the original

At a glance

  1. New staging: A (at risk), B (pre-HF), C (symptomatic HF), D (advanced HF). [e904]
  2. LVEF categories: HFrEF ≤40%, HFmrEF 41–49%, HFpEF ≥50%, plus HFimpEF (previously ≤40%, now >40%). [e905]
  3. HFrEF needs four drug classes: ARNI (or ACEi/ARB), an evidence-based beta-blocker, an MRA and an SGLT2i, all Class 1. Add diuretics as needed. [e924]
  4. ARNI is the preferred RAS inhibitor in NYHA II–III. Switch stable patients from ACEi or ARB to ARNI. [e928]
  5. SGLT2i: Class 1 in HFrEF, 2a in HFmrEF and HFpEF. [e932, e948, e949]
  6. Keep GDMT going in HFimpEF, even if the patient is now asymptomatic. [1, B-R · e948]
  7. Use natriuretic peptides to diagnose and to stratify risk (Class 1). Screen at-risk patients with NP (2a). [e911]

Stages and classification

Adapted from AHA/ACC/HFSA 2022 Figure 1, Table 3 and Table 4 [e904–e905]

Stage Who Key action
A: at risk Hypertension, CVD, diabetes, obesity, cardiotoxic drugs, genetic cardiomyopathy or family history. No symptoms, no structural disease Control risk factors
B: pre-HF No symptoms, but structural heart disease, raised filling pressures, or raised NP/troponin Prevent progression to symptomatic HF
C: symptomatic HF Current or previous symptoms with structural disease GDMT according to EF
D: advanced HF Marked symptoms affecting daily life, repeated admissions despite optimised GDMT Specialist care, MCS, transplant, palliative care
LVEF category Criteria
HFrEF LVEF ≤40%
HFimpEF Previous LVEF ≤40% and a follow-up LVEF >40%
HFmrEF LVEF 41–49% with evidence of raised LV filling pressure
HFpEF LVEF ≥50% with evidence of raised LV filling pressure

Trajectory within stage C

Patients whose symptoms resolve are still stage C. If symptoms, signs and structural abnormalities all resolve, the patient is described as HF in remission. [Figure 2 · e905]

Diagnosis

flowchart TD
    A["Suspected HF<br/>history · examination · ECG · labs"] --> B["Natriuretic peptide<br/>NT-proBNP ≥125 pg/mL or BNP ≥35 pg/mL"]
    B --> C["Transthoracic echocardiography<br/>(further tests if needed)"]
    C --> D["HF confirmed<br/>find the cause and classify"]
    D --> R["HFrEF<br/>LVEF ≤40%"]
    D --> M["HFmrEF<br/>LVEF 41–49%"]
    D --> P["HFpEF<br/>LVEF ≥50%"]
    R --> E["Look for precipitating factors<br/>start treatment"]
    M --> E
    P --> E
Adapted from AHA/ACC/HFSA 2022 Figure 4 [e907]

Class 1: initial tests [e910–e911]

  • Labs for every patient: FBC, urinalysis, electrolytes, urea, creatinine, glucose, lipids, LFTs, iron studies, TSH. Plus a 12-lead ECG. [1, C-EO]
  • BNP or NT-proBNP to support or exclude HF in a breathless patient, for risk stratification in chronic HF, and on admission for prognosis. [1, A]

Class 2a

  • In people at risk of HF, NP-based screening plus team-based care can prevent LV dysfunction or new HF. [2a, B-R]
  • A pre-discharge NP level helps predict prognosis after discharge. [2a, B-NR]

Stage A and B: prevention

Adapted from AHA/ACC/HFSA 2022 Figure 5 [e920]

Stage A (at risk) Recommendation Stage B (pre-HF) Recommendation
Hypertension Optimal BP control (1) LVEF ≤40% ACEi (1)
Type 2 diabetes with CVD or high CV risk SGLT2i (1) Recent MI and LVEF ≤40% ARB if ACEi not tolerated (1)
CVD Optimal CVD management (1) LVEF ≤40% Beta-blocker (1)
Cardiotoxic drug exposure Multidisciplinary evaluation (1) LVEF ≤30%, >1 year expected survival, >40 days post-MI ICD (1)
First-degree relative with genetic cardiomyopathy Genetic screening and counselling (1) Non-ischaemic cardiomyopathy Genetic counselling and testing (2a)
At risk NP screening (2a); validated risk scores (2a)

HFrEF (stage C and D)

flowchart TD
    S1["Step 1: confirm HFrEF (LVEF ≤40%), treat congestion, start GDMT<br/>ARNI (NYHA II–III) or ACEi/ARB (NYHA II–IV) · beta-blocker · MRA · SGLT2i<br/>diuretics as needed — all Class 1"] --> S2["Step 2: titrate to target doses as tolerated<br/>check labs, health status and LVEF"]
    S2 --> L{"LVEF now?"}
    L -- "LVEF ≤40%: persistent HFrEF" --> S3["Step 3: consider patient scenarios"]
    L -- "LVEF >40%: HFimpEF" --> C["Continue GDMT"]
    S3 --> H["NYHA III–IV, African American<br/>→ hydralazine + nitrate (1)"]
    S3 --> I["NYHA I–III, LVEF ≤35%, >1 year survival<br/>→ ICD (1)"]
    S3 --> R["NYHA II–ambulatory IV, LVEF ≤35%,<br/>sinus rhythm, LBBB with QRS ≥150 ms<br/>→ CRT-D (1)"]
    S3 --> O["Consider additional therapies"]
    H --> S5["Step 5: reassess symptoms, labs, health status, LVEF"]
    I --> S5
    R --> S5
    O --> S5
    S5 --> D["Refractory HF (stage D)<br/>Step 6: refer to HF specialty care<br/>durable MCS (1) · transplant (1)<br/>palliative care (1) · trials"]
    S5 --> C
Adapted from AHA/ACC/HFSA 2022 Figure 6 [e924]. Step 1 drugs can be started together at low doses, or one after another; target doses don't have to be reached before the next drug is added.

Class 1, LOE A: the four pillars

  • ARNI in NYHA II–III HFrEF. In stable NYHA II–III patients already on an ACEi or ARB, replace it with ARNI (1, B-R). [e928]
  • ACEi if ARNI isn't feasible. ARB if ACEi causes cough or angioedema and ARNI isn't feasible. [e928]
  • Beta-blocker: one of the three proven drugs (bisoprolol, carvedilol, metoprolol succinate). [e931]
  • MRA (spironolactone or eplerenone) in NYHA II–IV if eGFR >30 and K⁺ <5.0. Monitor potassium and renal function closely. [e931]
  • SGLT2i (dapagliflozin, empagliflozin) whether or not the patient has diabetes. [e932]
  • Titrate to the trial target doses unless not tolerated (1, A). It's reasonable to adjust every 1–2 weeks (2a). [e937]

Class 1: other drugs

  • Diuretics for fluid retention. Add metolazone (a thiazide) only if moderate- to high-dose loop diuretic doesn't work. [1, B-NR · e927]
  • Hydralazine + isosorbide dinitrate for patients self-identified as African American with NYHA III–IV on optimal therapy. [1, A · e933]

Class 3: harm or no benefit

  • ARNI within 36 hours of the last ACEi dose, or together with an ACEi. [3: Harm, B-R · e928]
  • ARNI or ACEi with any history of angioedema. [3: Harm, C-LD]
  • Continuing an MRA if K⁺ can't be kept <5.5. [3: Harm, B-NR · e931]
  • Non-DHP CCBs, class IC antiarrhythmics, dronedarone, thiazolidinediones, saxagliptin/alogliptin, NSAIDs in HFrEF. [3: Harm · e935]
  • DHP CCBs as a treatment for HF; vitamins, supplements and hormones except to correct a deficiency. [3: No benefit · e935]
  • Anticoagulation without a specific indication (AF, VTE, embolism). [3: No benefit, B-R · e934]

Drug doses

Adapted from AHA/ACC/HFSA 2022 Table 14 [e938]

Drug Starting dose Target dose
Sacubitril/valsartan 49/51 mg twice daily (24/26 mg twice daily possible) 97/103 mg twice daily
Enalapril 2.5 mg twice daily 10–20 mg twice daily
Ramipril 1.25–2.5 mg once daily 10 mg once daily
Lisinopril 2.5–5 mg once daily 20–40 mg once daily
Losartan 25–50 mg once daily 50–150 mg once daily
Valsartan 20–40 mg once daily 160 mg twice daily
Candesartan 4–8 mg once daily 32 mg once daily
Bisoprolol 1.25 mg once daily 10 mg once daily
Carvedilol 3.125 mg twice daily 25–50 mg twice daily
Metoprolol succinate 12.5–25 mg once daily 200 mg once daily
Spironolactone 12.5–25 mg once daily 25–50 mg once daily
Eplerenone 25 mg once daily 50 mg once daily
Dapagliflozin / empagliflozin 10 mg once daily 10 mg once daily
Isosorbide dinitrate + hydralazine (fixed dose) 20 mg + 37.5 mg three times daily 40 mg + 75 mg three times daily
Ivabradine 5 mg twice daily 7.5 mg twice daily
Vericiguat 2.5 mg once daily 10 mg once daily
Digoxin 0.125–0.25 mg daily Serum level 0.5–<0.9 ng/mL

Once GDMT is optimised: additional drugs

Adapted from AHA/ACC/HFSA 2022 Figure 7 [e940]

Patient Therapy Class
NYHA II–III, sinus rhythm, HR ≥70 on maximally tolerated beta-blocker Ivabradine 2a
NYHA II–IV, LVEF <45%, recent HF admission or IV diuretics, raised NP Vericiguat 2b
Symptomatic HFrEF despite GDMT Digoxin 2b
NYHA II–IV Omega-3 PUFA 2b
Hyperkalaemia on RAAS inhibitor Potassium binders 2b

Devices

flowchart TD
    A["HF on GDMT >3 months (>40 days if post-MI)<br/>or special pacing indication"] --> B{"Comorbidities limit<br/>survival to <1 year?"}
    B -- Yes --> N["Continue GDMT without a device"]
    B -- No --> E{"LVEF?"}
    E -- "36–50%" --> HB["High-degree or complete heart block<br/>→ CRT (2a)"]
    E -- "≤35%" --> Q{"NYHA class / situation"}
    Q -- "NYHA I" --> N1["LVEF ≤30%, ischaemic,<br/>LBBB ≥150 ms → CRT (2b)"]
    Q -- "NYHA II to ambulatory IV" --> Q2["LBBB ≥150 ms → CRT (1)<br/>non-LBBB ≥150 ms → CRT (2a)<br/>LBBB 120–149 ms → CRT (2a)<br/>non-LBBB 120–149 ms → CRT (2b)"]
    Q -- "Special circumstances" --> SP["AF, or sinus rhythm,<br/>with frequent or expected RV pacing<br/>→ CRT (2a)"]
Adapted from AHA/ACC/HFSA 2022 Figure 8 [e943]

Class 1: ICD for primary prevention [e941]

  • Non-ischaemic DCM, or ischaemic heart disease ≥40 days post-MI, with LVEF ≤35%, NYHA II–III on GDMT and expected survival >1 year. [1, A]
  • ≥40 days post-MI with LVEF ≤30% and NYHA I. [1, B-R]

Class 3: no benefit [e942]

  • CRT with QRS <120 ms.
  • CRT in NYHA I–II with non-LBBB and QRS <150 ms.
  • ICD or CRT-D when comorbidities or frailty limit survival to under 1 year.

Other procedures [Figure 9 · e944]

  • Transcatheter edge-to-edge mitral repair (2a): NYHA II–IV, severe secondary MR, suitable anatomy, LVEF 20–50%, LVESD ≤70 mm, PASP ≤70 mmHg, after GDMT is optimised.
  • Surgical revascularisation (1): selected patients with LVEF ≤35% and suitable coronary anatomy.
  • Wireless PA pressure monitoring (2b): NYHA III with a recent admission or raised NP.

HFmrEF, HFimpEF and HFpEF

Adapted from Figure 11 [e948]

Therapy Class
Diuretics as needed 1
SGLT2i 2a
ACEi, ARB or ARNI 2b
MRA 2b
Evidence-based beta-blocker 2b

The Class 2b drugs work best at the lower end of the EF range. Repeat the LVEF to see which way the patient is heading.

Class 1 [e948]

  • Continue GDMT to prevent relapse, even if the patient is now asymptomatic. [1, B-R]

Adapted from Figure 12 [e950]

Therapy Class
Diuretics as needed 1
BP control to guideline targets 1
SGLT2i 2a
AF management 2a
ARNI* 2b
MRA* 2b
ARB* 2b

*More benefit when LVEF is closer to 50%.

Class 3: no benefit [e949]

  • Routine nitrates or PDE-5 inhibitors to improve activity or quality of life.

Comorbidities

Adapted from AHA/ACC/HFSA 2022 Figure 14 [e970]

Patient Therapy Class
HF + hypertension Treat to hypertension guideline targets; uptitrate GDMT 1
HF + type 2 diabetes SGLT2i 1
HF + AF with CHA₂DS₂-VASc ≥2 (men) or ≥3 (women) Anticoagulation 1
HFrEF + iron deficiency IV iron 2a
HF with symptoms from AF AF ablation 2a
AF, LVEF ≤50%, rate uncontrolled after failed rhythm control AV node ablation + CRT 2a
HF + obstructive sleep apnoea CPAP 2a

Class 3: harm [e969]

  • Erythropoiesis-stimulating agents for anaemia in HF. [3: Harm, B-R]
  • Adaptive servo-ventilation in NYHA II–IV HFrEF with central sleep apnoea. [3: Harm, B-R]

Clinical pearls

  • NNT for all-cause mortality over 12 months (Table 15, e939): MRA 18, beta-blocker 28, ICD 70, ARNI 80 (on top of ACEi), SGLT2i 63.
  • Pre-HF (stage B) can't have symptoms, current or past. Once a patient has had symptoms, they're stage C for good, even after recovery.
  • HFmrEF and HFpEF diagnoses need evidence of raised filling pressure, not just an EF number.
  • Dietary sodium: just "avoid excessive intake" (2a, C-LD). There's no fixed target. [e925]

Classes and levels of evidence

How AHA/ACC/HFSA 2022 grades its recommendations. Adapted from AHA/ACC/HFSA 2022 Table 2 (updated May 2019) [e903]. Hover over any class or level cited on this page to see what it means.

Class Strength Meaning Wording used
Class 1 Strong Benefit >>> risk is recommended; is indicated, useful, effective or beneficial; should be performed or administered
Class 2a Moderate Benefit >> risk is reasonable; can be useful, effective or beneficial
Class 2b Weak Benefit ≥ risk may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain
Class 3: No benefit Moderate Benefit = risk (generally used only with level A or B) is not recommended; is not indicated, useful or effective; should not be performed or administered
Class 3: Harm Strong Risk > benefit potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered
Level Meaning
Level A High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies
Level B-R (randomised) Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs
Level B-NR (non-randomised) Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies
Level C-LD (limited data) Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans
Level C-EO (expert opinion) Consensus of expert opinion based on clinical experience

Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.